Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Time Posted：2024-11-15 16:47
Following the launch of a new generation of innovative glucocorticoid drugs and the entry of an innovative asthma GSNOR inhibitor into Phase II, HealthGen has again reported good news in the field of respiratory innovative drugs. Recently, the company's MABA dual-target innovative drug for chronic obstructive pulmonary disease (COPD) has shown good safety in Phase I trials and has officially entered Phase II clinical trials and enrolled the first patient, marking another solid step towards commercialization.
Time Posted：2024-11-08 17:05
On October 16, HealthGen's novel S-nitrosoglutathione reductase (GSNOR) inhibitor successfully enrolled its first subject in a Phase II clinical study, marking a key step in exploring new treatment options for moderate and severe asthma.
Time Posted：2024-11-07 16:01
On November 5th, the "Chronic Disease Public Welfare Supporting Rural Revitalization" initiative, jointly promoted by Health Gen and Lizhu Group, visited Sunan County, Gansu Province. A donation ceremony was held in the second-floor meeting room of the County Committee Party School. Sunan County leaders Chou Shengrong, Zhang Aixia, and Fang Yuepeng, representatives from some townships, relevant county-level units, county-level medical and health units, and volunteers from Health Gen and Lizhu Group attended the ceremony.
Time Posted：2024-10-31 15:30
Recently, Healthy Yuan Pharmaceutical Group announced the launch of a new small molecule glucocorticoid drug. This drug targets respiratory diseases such as COPD, bronchial asthma, and rhinitis, and can provide patients with a more effective treatment plan by activating specific receptor activity.
The "Top 100 Private Enterprises in Guangdong Province 2024" list has been released
Time Posted：2024-10-29 11:00
On October 29, the "Top 100 Private Enterprises in Guangdong Province 2024" list was officially released.
Time Posted：2024-10-17 09:20
In recent years, thanks to the positive guidance of regulatory policies, China's capital market has gradually matured. Especially after the promulgation and implementation of the new "Nine Articles" policy, the pace of high-quality development of the capital market has significantly accelerated. The new "Nine Articles" policy particularly highlights the key role of the shareholder return mechanism and strongly advocates that listed companies adopt measures such as cash dividends and share buybacks to enhance returns for investors. Against this backdrop, HealthGen (600380.SH) has actively implemented various methods such as cash dividends and share buybacks to share the fruitful results of the company's development with its shareholders. Its series of high-frequency measures in the area of shareholder returns in recent years are particularly noteworthy.
Time Posted：2024-10-13 11:10
Recently, the Shenzhen Stock Exchange (hereinafter referred to as "SZSE") announced the results of its 2023-2024 information disclosure evaluation for A-share listed companies on the main board. LiZhu Group was awarded an A rating (the highest), marking the fifth consecutive year the company has received this recognition. This is a testament to the SZSE's high regard for the company's information disclosure quality, investor relations, and sustainable development efforts.
For four consecutive years! Healthy Yuan has once again been awarded the Shanghai Stock Exchange's
Time Posted：2024-10-12 18:05
Recently, the Shanghai Stock Exchange (hereinafter referred to as the SSE) released the "Evaluation Results of Information Disclosure Work of Shanghai Main Board Listed Companies in 2023-2024". HealthGen (600380), with its solid operating performance, standardized corporate operation, high-quality information disclosure, and good investor relations management, once again received the highest rating of "A" (Excellent) in the SSE's 2023-2024 information disclosure work assessment. This is the fourth consecutive year the company has received this honor.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.